Company intelligence / Profile preview

OmicEra Diagnostics

Planegg/Martinsried near Munich, Bavaria, Germanyizb-online.de ↗

Ownership: Private
Development stage: Commercial

Overview

OmicEra developed a leading-edge platform combining mass spectrometry-based proteomics with AI to discover novel biomarkers for early disease detection. The company was acquired by Exact Sciences in May 2022 to enhance their R&D capabilities in cancer diagnostics. Clinical results are not applicable as the company provides analytical services rather than therapeutics.

Therapeutic areas: OncologyOther
Modalities: Diagnostic platformProteomics-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Exact Sciences (acquirer/parent; strategic partnership post-acquisition)

Beyond the preview

Go deeper on OmicEra Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmicEra Diagnostics.

Explore the full profile